|Treating the Patient with High-risk MDS: Practical Strategies and Emerging Therapeutic Options|
David A. Sallman, MD
|Release Date: October 23, 2019|
Expiration Date: October 23, 2020
Almost one-third of patients are classified as higher risk with a median overall survival of less than 1.5 years. In this activity, Dr. David Sallman covers which factors will impact the selections of therapy. Additionally, he will review ongoing clinical trials of novel agents and combinations while outlining where these practice strategies and trials can be utilized.Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Astex Pharmaceuticals, Celgene Corporation, and Takeda Oncology.
|Begin, Earn CreditView Only, No Credit|